Frontiers in antibiotics最新文献

筛选
英文 中文
A retrospective review of the common childhood illnesses and the indications for antibiotic prescription at community hospital in Malawi. 马拉维社区医院常见儿童疾病及抗生素处方指征的回顾性分析。
Frontiers in antibiotics Pub Date : 2024-09-05 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1447435
Adriano Focus Lubanga, Chana Khuluza, Jamillah Muhyuddin, Reuben Simfukwe, Frank Kaphesi, Yeo Hwan Yeum, Joshua J Yoon, Changwoo Kim, Seunghyun Kim, Si Yeon Kim, Ji An Lee, Jooheon Park, David Kim, Akim Nelson Bwanali, Lee Woohyung, Thomas Nyirenda
{"title":"A retrospective review of the common childhood illnesses and the indications for antibiotic prescription at community hospital in Malawi.","authors":"Adriano Focus Lubanga, Chana Khuluza, Jamillah Muhyuddin, Reuben Simfukwe, Frank Kaphesi, Yeo Hwan Yeum, Joshua J Yoon, Changwoo Kim, Seunghyun Kim, Si Yeon Kim, Ji An Lee, Jooheon Park, David Kim, Akim Nelson Bwanali, Lee Woohyung, Thomas Nyirenda","doi":"10.3389/frabi.2024.1447435","DOIUrl":"10.3389/frabi.2024.1447435","url":null,"abstract":"<p><strong>Background: </strong>Childhood remains a vulnerable period and a key determiner for adult health. Various illnesses experienced by children in their early years determine future performance and contribution to society. Acute and chronic infectious diseases, undernutrition, and early childhood non-communicable diseases have greatly been linked to intellectual disability, poor childhood development, increased morbidity, and household and healthcare economic costs. In most developing countries, infections contribute to a larger burden of disease. Despite this being the case, most developing countries have a limited range of diagnostic capacity and access to a wide range spectrum of WHO Access, Watch and Reserve antibiotics. This leads to overuse and misuse of the available antibiotics and a wide range spread of resistance strains. In this study, we evaluated common childhood presentations and indications for antibiotic prescriptions at a community hospital in Malawi.</p><p><strong>Objective: </strong>This study analyzed common childhood Clinical Presentations and antibiotic prescription patterns at the pediatric outpatient department (OPD) at St. Gabriel Community Mission Hospital in Malawi.</p><p><strong>Methods: </strong>A retrospective search of all outpatient routinely corrected data from St. Gabriel Community Mission Hospital between January to December 2022 was carried out. Manual screening was done on all appropriate routines under 14 medical records, and prespecified variables were extracted. Data collected consisted of total OPD patient number, age, sex, diagnosis and prescription.</p><p><strong>Results: </strong>A total of 2711 children under 15 years of age were included, with 53.9% being males. The majority of them were below the age of 5 (59.5%). 30% of the cases seen in the department were attributable to respiratory presentation, representing the majority of the cases seen. Sepsis and enteric diseases also constituted the majority of the cases seen and contributed 18% and 7% respectively. 68% per cent of the children seen during the period of the study had an antibiotic prescription, with the majority having only one antibiotic prescribed (31.7%). Overall, amoxicillin constituted the most commonly prescribed antibiotic for the whole system, while metronidazole was the most commonly prescribed antibiotic among enteric illnesses. Being under five was associated with a higher likelihood of antibiotic prescription (p <0.001). There were no significant differences in antibiotic prescription by gender and prescribing quarter of the year.</p><p><strong>Conclusion: </strong>Our findings suggest that there could be overuse and misuse of antibiotics within community hospitals. Overuse and misuse of antibiotics at the community level is closely linked to limited cytobacteriological testing, and limited access to all categories of antibiotics. Amid limited resources, more research is needed to understand the barriers and facilitators t","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1447435"},"PeriodicalIF":0.0,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practices, strategies, and challenges in antibiotic treatment and prevention of antimicrobial resistance from the perspectives of Romanian community pharmacists and general practitioners: a Goffman-inspired qualitative interview study. 从罗马尼亚社区药剂师和全科医生的角度来看,抗生素治疗和预防抗菌素耐药性的实践、策略和挑战:戈夫曼启发的定性访谈研究。
Frontiers in antibiotics Pub Date : 2024-09-04 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1439688
Lavinia Bianca Balea, Stinne Glasdam
{"title":"Practices, strategies, and challenges in antibiotic treatment and prevention of antimicrobial resistance from the perspectives of Romanian community pharmacists and general practitioners: a Goffman-inspired qualitative interview study.","authors":"Lavinia Bianca Balea, Stinne Glasdam","doi":"10.3389/frabi.2024.1439688","DOIUrl":"10.3389/frabi.2024.1439688","url":null,"abstract":"<p><strong>Introduction: </strong>Antimicrobial resistance (AMR) represents a persistent and ascensive global threat influenced by antibiotic misuse and overuse. In the Romanian context, patterns of antibiotic consumption and resistance within the healthcare system are marked in the red scenario on the European map. General practitioners and pharmacists, among others, play a major role in stewardship towards AMR.</p><p><strong>Aim: </strong>To explore the practices, strategies, and challenges in antibiotic treatment and prevention of antimicrobial resistance from the perspectives of Romanian community pharmacists and general practitioners.</p><p><strong>Method and materials: </strong>Semi-structured interviews were conducted with six general practitioners and five community pharmacists in Romania from January to March 2024. An inductive, Goffman theory-inspired thematic analysis was conducted, inspired by Braun and Clarke's thematic analysis method, consisting of familiarization with the data, iterative coding guided by theoretically inspired questions, and identification and refinement of (sub)themes. Goffman's theory of social interaction, focusing on the concepts of front stage, backstage, and roles, guided the analytical questions.</p><p><strong>Results: </strong>The results were presented in three overarching themes: 'Knowledge acquired backstage to support challenges and performance on front stage', 'Adapting roles and performances on the front stage: A mix of structured and twisted acts', and 'Interprofessional Collaboration: A latent part in the play's roles and performances'. Professionals prepared their understandings of AMR and antibiotics backstage, with an awareness of the challenges rooted in the Romanian context. The front stage scenario evolved from structured antibiotic performances led by AMR strategies with compliant actors to challenging performances influenced by actors which changed the course of performances and intended AMR strategies. The revealed competition between general practitioners and pharmacists further complicated antibiotic use and AMR-related performances.</p><p><strong>Conclusion: </strong>The Romanian socio-political system influenced the course of antibiotic treatment and the professionals' intended antibiotic related practices and AMR strategies. The study showed a theory-practice gap in health professionals' practices, leading to limited strategy integration towards AMR and increased antibiotic use. The study underscores the need for context-specific policies and interventions to minimize identified gaps.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1439688"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acinetobacter spp. in neonatal sepsis: an urgent global threat. 新生儿败血症中的不动杆菌:一个紧迫的全球威胁。
Frontiers in antibiotics Pub Date : 2024-09-03 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1448071
Kamla Pillay, Anirban Ray-Chaudhuri, Seamus O'Brien, Paul Heath, Mike Sharland
{"title":"<i>Acinetobacter</i> spp. in neonatal sepsis: an urgent global threat.","authors":"Kamla Pillay, Anirban Ray-Chaudhuri, Seamus O'Brien, Paul Heath, Mike Sharland","doi":"10.3389/frabi.2024.1448071","DOIUrl":"10.3389/frabi.2024.1448071","url":null,"abstract":"<p><p>Neonatal sepsis causes substantial morbidity and mortality, the burden of which is carried by low-income countries (LICs). The emergence of multidrug-resistant pathogens in vulnerable neonatal populations poses an urgent threat to infant survival. <i>Acinetobacter</i> spp. are increasingly responsible for severe disease in neonates globally. The cause of this escalation remains unclear, but host, pathogen and environmental factors are all likely to contribute. <i>Acinetobacter</i> spp. strains are frequently resistant to the first line empirical treatment for neonatal sepsis as recommended by the World Health Organization (WHO), ampicillin and gentamicin, rendering these antibiotics ineffectual in many critically ill neonates. The resultant escalation to broader spectrum antibiotic regimens in neonatal intensive care units (NICUs) worldwide has led to the emergence of more resistant strains, including carbapenem-resistant <i>Acinetobacter baumanii</i> (CRAB), resulting in infections that are ever more difficult to treat. While some existing antimicrobial agents are under consideration for treatment of <i>Acinetobacter</i> spp. infections, the majority remain a long way from clinical use in neonates. Further research into the clinical phenotype of these infections, transmission dynamics and preventative measures are urgently needed to reduce neonatal deaths. This review aims to summarise the role of <i>Acinetobacter</i> spp. in neonatal sepsis, including host, pathogen and environmental factors, the global epidemiology and clinical features of the disease, the treatment options, and future research priorities.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1448071"},"PeriodicalIF":0.0,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vitro antimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010–2021 约旦成人和儿科患者临床分离物的体外抗菌药物敏感性:2010-2021 年抗菌药物测试领导和监测(ATLAS)
Frontiers in antibiotics Pub Date : 2024-08-08 DOI: 10.3389/frabi.2024.1375980
Dima Al Jammal, Julia Bachir, Jihane A. Moussa, Jamal Wadi Al Ramahi
{"title":"In vitro antimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010–2021","authors":"Dima Al Jammal, Julia Bachir, Jihane A. Moussa, Jamal Wadi Al Ramahi","doi":"10.3389/frabi.2024.1375980","DOIUrl":"https://doi.org/10.3389/frabi.2024.1375980","url":null,"abstract":"To evaluate the in vitro antimicrobial susceptibilities of Gram-positive and Gram-negative isolates from patients in Jordan between 2010 and 2021, through the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme.Medical centres in Jordan collected bacterial isolates from hospitalised patients with defined infection sources between 2010 and 2021 (no isolates collected in 2014). Antimicrobial susceptibility was interpreted using CLSI standards. FDA-approved breakpoints were applied for tigecycline. The identification of β-lactamase genes was performed for a proportion of isolates using multiplex PCR assays.More than 92% of Acinetobacter baumannii collected were multidrug-resistant (MDR) and/or carbapenem-resistant (CR), and > 50% susceptibility was reported only to minocycline (62.2% among both MDR and CR isolates). Rates of MDR and CR Pseudomonas aeruginosa were 14.3% and 20.5%, respectively, and among all P. aeruginosa collected from adults, susceptibility to ceftazidime/avibactam was 95.3% and to ceftolozane/tazobactam was 88.4%. For Escherichia coli from adults and MDR E. coli, susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam, imipenem, meropenem and meropenem/vaborbactam was 92.1%–98.7%. Susceptibility to tigecycline was > 94% among Klebsiella pneumoniae from adult, paediatric, and ICU patients (all ages). CTX-M-15 was the most frequently identified β-lactamase gene among E. coli and K. pneumoniae. Susceptibility to most antimicrobial agents was < 50% among K. pneumoniae carrying CTX-M-15, CTX-M-9-type, NDM-5, and/or OXA-48 β-lactamase genes. All S. aureus collected were susceptible to teicoplanin, vancomycin, daptomycin, linezolid and tigecycline, with 96.1% of S. aureus from adults were susceptible to ceftaroline. Overall, 58.8% of Staphylococcus aureus were MRSA.This study provides valuable information regarding antimicrobial susceptibility in Jordan between 2010 and 2021. Continued monitoring of in vitro antimicrobial susceptibility is critical in the fight against antimicrobial resistance.","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"30 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141927610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genomic modifications for enhanced antibiotic production in rifamycin derivative-producing Amycolatopsis mediterranei S699 strains: focusing on rifQ and rifO genes. 产利福霉素衍生物的地中海Amycolatopsis S699菌株增强抗生素生产的基因组修饰:聚焦于rifQ和rifO基因。
Frontiers in antibiotics Pub Date : 2024-06-24 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1399139
Moritz Müller, Elena Bialas, Irina Sturm, Utkarsh Sood, Rup Lal, Andreas Bechthold
{"title":"Genomic modifications for enhanced antibiotic production in rifamycin derivative-producing <i>Amycolatopsis mediterranei</i> S699 strains: focusing on <i>rifQ</i> and <i>rifO</i> genes.","authors":"Moritz Müller, Elena Bialas, Irina Sturm, Utkarsh Sood, Rup Lal, Andreas Bechthold","doi":"10.3389/frabi.2024.1399139","DOIUrl":"10.3389/frabi.2024.1399139","url":null,"abstract":"<p><p>Rifamycin and its derivatives are natural products that belong to the class of antibiotic-active polyketides and have significant therapeutic relevance within the therapy scheme of tuberculosis, a worldwide infectious disease caused by <i>Mycobacterium tuberculosis</i>. Improving the oral bioavailability of rifamycin B was achieved through semisynthetic modifications, leading to clinically effective derivatives such as rifampicin. Genetic manipulation of the rifamycin polyketide synthase gene cluster responsible for the production of rifamycin B in the <i>Amycolatopsis mediterranei</i> strain S699 represents a promising tool to generate new rifamycins. These new rifamycins have the potential to be further derivatized into new, ideally more effective, clinically usable compounds. However, the resulting genetically engineered strains only produce these new derivatives in low yields. One example is the strain DCO36, in which <i>rif</i>AT6 was replaced by <i>rap</i>AT2, resulting in the production of rifamycin B and the new derivative 24-desmethyl rifamycin B. Here we describe the successful method adaptation of the PCR-targeting <i>Streptomyces</i> gene replacement approach to <i>Amycolatopsis mediterranei</i> S699 and further on the implementation of genetic modifications that enable an increased production of the derivative 24-desmethyl rifamycin B in the mutant strain DCO36. The described genetic modifications resulted in a mutant strain of DCO36 with <i>rifQ</i> deletion showing a 62% increase in 24-desmethyl rifamycin B production, while a mutant with <i>rifO</i> overexpression showed a 27% increase.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1399139"},"PeriodicalIF":0.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Antimicrobial resistance in food-producing environments: a One Health approach. 社论:食品生产环境中的抗菌素耐药性:同一个健康方针。
Frontiers in antibiotics Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1436987
Getahun E Agga, Kebede Amenu
{"title":"Editorial: Antimicrobial resistance in food-producing environments: a One Health approach.","authors":"Getahun E Agga, Kebede Amenu","doi":"10.3389/frabi.2024.1436987","DOIUrl":"10.3389/frabi.2024.1436987","url":null,"abstract":"","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1436987"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731954/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A machine learning-based strategy to elucidate the identification of antibiotic resistance in bacteria. 一种基于机器学习的策略来阐明细菌抗生素耐药性的鉴定。
Frontiers in antibiotics Pub Date : 2024-06-18 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1405296
K T Shreya Parthasarathi, Kiran Bharat Gaikwad, Shruthy Rajesh, Shweta Rana, Akhilesh Pandey, Harpreet Singh, Jyoti Sharma
{"title":"A machine learning-based strategy to elucidate the identification of antibiotic resistance in bacteria.","authors":"K T Shreya Parthasarathi, Kiran Bharat Gaikwad, Shruthy Rajesh, Shweta Rana, Akhilesh Pandey, Harpreet Singh, Jyoti Sharma","doi":"10.3389/frabi.2024.1405296","DOIUrl":"10.3389/frabi.2024.1405296","url":null,"abstract":"<p><p>Microorganisms, crucial for environmental equilibrium, could be destructive, resulting in detrimental pathophysiology to the human host. Moreover, with the emergence of antibiotic resistance (ABR), the microbial communities pose the century's largest public health challenges in terms of effective treatment strategies. Furthermore, given the large diversity and number of known bacterial strains, describing treatment choices for infected patients using experimental methodologies is time-consuming. An alternative technique, gaining popularity as sequencing prices fall and technology advances, is to use bacterial genotype rather than phenotype to determine ABR. Complementing machine learning into clinical practice provides a data-driven platform for categorization and interpretation of bacterial datasets. In the present study, k-mers were generated from nucleotide sequences of pathogenic bacteria resistant to antibiotics. Subsequently, they were clustered into groups of bacteria sharing similar genomic features using the Affinity propagation algorithm with a Silhouette coefficient of 0.82. Thereafter, a prediction model based on Random Forest algorithm was developed to explore the prediction capability of the k-mers. It yielded an overall specificity of 0.99 and a sensitivity of 0.98. Additionally, the genes and ABR drivers related to the k-mers were identified to explore their biological relevance. Furthermore, a multilayer perceptron model with a hamming loss of 0.05 was built to classify the bacterial strains into resistant and non-resistant strains against various antibiotics. Segregating pathogenic bacteria based on genomic similarities could be a valuable approach for assessing the severity of diseases caused by new bacterial strains. Utilization of this strategy could aid in enhancing our understanding of ABR patterns, paving the way for more informed and effective treatment options.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1405296"},"PeriodicalIF":0.0,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Microbiology: where do we stand? 临床微生物学:我们站在哪里?
Frontiers in antibiotics Pub Date : 2024-06-17 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1250632
Alkiviadis Vatopoulos
{"title":"Clinical Microbiology: where do we stand?","authors":"Alkiviadis Vatopoulos","doi":"10.3389/frabi.2024.1250632","DOIUrl":"10.3389/frabi.2024.1250632","url":null,"abstract":"<p><p>Clinical Microbiology has developed during the last 100 years, simultaneous with the discovery of microorganisms as causes of infections. Globalization and One Health determine present needs whereas molecular biology, automation, artificial intelligence, and bioinformatics are new tools that characterize the new developments in the field.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1250632"},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review. 优化治疗危重原位肝移植受者革兰氏阴性感染的β -内酰胺的药代动力学/药效学问题:全面回顾
Frontiers in antibiotics Pub Date : 2024-06-17 eCollection Date: 2024-01-01 DOI: 10.3389/frabi.2024.1426753
Milo Gatti, Federico Pea
{"title":"Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review.","authors":"Milo Gatti, Federico Pea","doi":"10.3389/frabi.2024.1426753","DOIUrl":"10.3389/frabi.2024.1426753","url":null,"abstract":"<p><p>Orthotopic liver transplant (OLT) represents the standard of care for managing patients affected by end-stage and life-threatening liver diseases. Although a significant improvement in surgical techniques, immunosuppressant regimens, and prompt identification of early post-transplant complications resulted in better clinical outcome and survival in OLT recipients, the occurrence of early bacterial infections still represents a remarkable cause of morbidity and mortality. In this scenario, beta-lactams are the most frequent antimicrobials used in critical OLT recipients. The aim of this narrative review was to provide a comprehensive overview of the pathophysiological issues potentially affecting the pharmacokinetics of beta-lactams and to identify potential strategies for maximizing the likelihood of attaining adequate pharmacokinetic/pharmacodynamic (PK/PD) targets of beta-lactams in critically ill OLT recipients. A literature search was carried out on PubMed-MEDLINE database (until 31<sup>st</sup> March 2024) in order to retrieve clinical trials, real-world observational evidence, and/or case series/reports evaluating the PK/PD of traditional and novel beta-lactams in settings potentially involving critically ill OLT recipients. Retrieved evidence were categorized according to the concepts of the so-called \"antimicrobial therapy puzzle\", specifically assessing a) beta-lactam PK/PD features, with specific regard to aggressive PK/PD target attainment; b) site of infection, with specific regard to beta-lactam penetration in the lung, ascitic fluid, and bile; and c) pathophysiological alterations, focusing mainly on those specifically associated with OLT. Overall, several research gaps still exist in assessing the PK behavior of beta-lactams in critical OLT recipients. The impact of specific OLT-associated pathophysiological alterations on the attainment of optimal PK/PD targets may represent an important field in which further studies are warranted. Assessing the relationship between aggressive beta-lactam PK/PD target attainment and clinical outcome in critical OLT recipients will represent a major challenge in the next future.</p>","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":"3 ","pages":"1426753"},"PeriodicalIF":0.0,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143017422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: Antibiotics in engineered and natural environments: occurrence, fate, kinetic and microbial impact 社论:工程和自然环境中的抗生素:发生、归宿、动力学和微生物影响
Frontiers in antibiotics Pub Date : 2024-06-07 DOI: 10.3389/frabi.2024.1437802
I. Pala-Ozkok, Tugce Katipoglu-Yazan
{"title":"Editorial: Antibiotics in engineered and natural environments: occurrence, fate, kinetic and microbial impact","authors":"I. Pala-Ozkok, Tugce Katipoglu-Yazan","doi":"10.3389/frabi.2024.1437802","DOIUrl":"https://doi.org/10.3389/frabi.2024.1437802","url":null,"abstract":"","PeriodicalId":73065,"journal":{"name":"Frontiers in antibiotics","volume":" 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141372908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信